SANTA ROSA, CA – September 15, 2009 – Osseon Therapeutics Inc., a Santa Rosa, California manufacturer of novel medical devices for the minimally invasive treatment of spinal compression fractures today announced it has signed a five-year agreement with MBA Incorporado, SL to distribute Osseon’s suite of products in the European and South American markets. MBA is a leading medical device marketing and distribution organization and specializes in the sale of products used for treatment of the spine. MBA is the largest private independent distributor of orthopedic devices in Europe, generating more than $100 million in total sales in 2008.
Osseon’s product line features the Osseoflex and Osseoperm. These products combine to form a unique new procedure termed Osseoplasty to treat painful acute fractures of the vertebrae seen increasingly in older individuals with osteoporosis and osteo-metastatic injuries.
Osseoflex is a steerable and curvable needle that can access the majority of the vertebral body from a single percutaneous access point. The Osseoperm system is customized for delivering optimal viscosity cement and precise cement placement through the Osseoflex needle. The Osseoplasty procedure provides rapid stabilization of vertebral fractures and significant pain relief in most patients within the same day.
MBA will distribute Osseon’s devices to physicians and hospitals throughout the European Union, including the United Kingdom, Germany, Spain, Portugal, Italy, Greece, Austria, Switzerland, Scandinavia, France, Benelux, Turkey and Germany, as well as Latin America.
“Osseon is excited to partner with MBA, the leading distributor of biomedical spine treatment products in Europe and South America, said Dr. John Stalcup, CEO of Osseon Therapeutics. “MBA is known as the “state-of-the-science” innovator in these markets for medical devices, always at the forefront of distribution and support of advanced medical technologies. Having MBA as our exclusive distributor will bring immediate and long-lasting relationships with the leading physicians and hospitals treating spinal compression fractures. We are, indeed, pleased to have MBA as our sole representative.”
Paul Griffin, MBA's Chief Operating Officer and a member of their Board of Directors said "MBA is honored that Osseon has chosen our Organization as its marketing and distribution partner for this unique technology for Europe and South America. We are delighted with this Agreement, which represents a huge opportunity for both our Organisations to facilitate the introduction of this exciting and new therapeutic option to specialists in many countries outside the U.S., who are treating an ever-increasing number of painful vertebral compression fractures in older patients." Paul Griffin added, "We feel confident that the combination of Osseon's impressive product portfolio together with MBA's experienced team and marketing know-how will allow us to develop and grow a very successful business together as innovators in this key market. Osseon has state-of-the-art technology and MBA has the resources to bring these remarkable devices quickly and successfully into all of the major and most competitive markets outside the U.S."
"MBA has an excellent and long-established international reputation for marketing and distributing medical devices for independent innovators and an unparalleled reputation for customer service. The Agreement today between MBA and Osseon represents a major step forward in the expansion of these services into the key markets of Europe and Latin America."
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union. For more information, visit our web site at www.osseon.com.
Osseon® is a registered trademark of Osseon Therapeutics, Inc.
CONTACT: Michael Bivens, Director of Business Development, Osseon Therapeutics, 707.636.5953